Camizestrant clinical trials
Camizestrant is named as an intervention in 13 current clinical trials in our USA, Spain, UK, South Korea, Germany, Italy, Poland, Canada, France, Portugal, Japan, Australia, China, Belgium, Austria, Czechia, Turkey, Taiwan, Israel, India, Switzerland, Brazil, Mexico, Norway, Ireland, Netherlands and Singapore registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (11). The most-studied condition is ER-Positive HER2-Negative Breast Cancer. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Where Camizestrant is approved
All regulators →Of the three regulators tracked here, the first to approve Camizestrant was the EU, on 20 Jul 2026. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Camizestrant patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Camizestrant, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 6 listed patents; the last listed expires 22 Oct 2041 (US 12453729).
- Latest patent on the drug substance itself: 13 Oct 2037 (US 10590130).
- Exclusivity NCE: New chemical entity, until 4 Sep 2031.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Camizestrant works
All drug targets →- Estrogen receptor alpha degrader DegraderTarget: ESR1 estrogen receptor 1✓ In ChEMBL and the Guide to Pharmacology
- Breast cancerPhase 3
- Ovarian cancerPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4650365, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12716, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Camizestrant
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: EtcamahEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Camizestrant
13 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Camizestrant in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Camizestrant. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer
2025-524213-84-00 · Neoplasms
|
Phase 3 | Authorised | Unicancer | France |
|
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER (THE CADILLAC STUDY)
2024-520027-88-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Ongoing | Medica Scientia Innovation Research S.L | Spain, Germany, Italy |
Camizestrant across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
1 single-substance product containing Camizestrant on the HPRA medicines list.
- ETCAMAH 75 mg film-coated tabletsAstraZeneca AB · EU/1/26/2046/001
Supply shortages
No entry for Camizestrant in the EMA, FDA or German BfArM shortage lists we track.
Recent approvals
- EtcamahEMA · 20 Jul 2026 · AstraZeneca AB
Conditions studied with Camizestrant
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| ER-Positive HER2-Negative Breast Cancer | 3 |
| Breast Cancer, Early Breast Cancer | 2 |
| ER+ HER2- Advanced Breast Cancer | 2 |
| Advanced Breast Cancer | 2 |
| Breast Cancer | 2 |
| High-grade Serous Ovarian Cancer (HGSOC) | 1 |
| Ovarian Cancer | 1 |
| Pancreatic Cancer | 1 |
| Prostate Cancer | 1 |
| Hormon Receptor Positive Breast Cancer | 1 |
| Estrogen Receptor-positive | 1 |
| Early Stage Endometrial Cancer | 1 |
| Advanced ER-Positive HER2-Negative Breast Cancer | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 11 |
| MedSIR | 1 |
| University Health Network, Toronto | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Camizestrant trials
How many clinical trials are testing Camizestrant?
13 current trials in our USA, Spain, UK, South Korea, Germany, Italy, Poland, Canada, France, Portugal, Japan, Australia, China, Belgium, Austria, Czechia, Turkey, Taiwan, Israel, India, Switzerland, Brazil, Mexico, Norway, Ireland, Netherlands and Singapore registers name Camizestrant (also registered as AZD9833) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Camizestrant trials recruiting patients?
Yes. 5 of the 13 trials are recruiting: 4 with sites in USA, 4 with sites in Spain, 3 with sites in UK, 3 with sites in South Korea, 4 with sites in Germany, 3 with sites in Italy, 3 with sites in Poland, 2 with sites in Canada, 3 with sites in France, 2 with sites in Portugal, 2 with sites in Japan, 2 with sites in Australia, 2 with sites in China, 1 with sites in Belgium, 2 with sites in Austria, 2 with sites in Czechia, 2 with sites in Turkey, 2 with sites in Taiwan, 2 with sites in Israel, 2 with sites in India, 1 with sites in Switzerland, 2 with sites in Brazil, 1 with sites in Mexico, 1 with sites in Netherlands and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Camizestrant clinical trials?
AstraZeneca (11), MedSIR (1) and University Health Network, Toronto (1). The number in brackets is how many trials each organisation leads.
Are there Camizestrant clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Camizestrant licensed in Ireland?
Yes. The HPRA medicines list includes 1 single-substance product containing Camizestrant, for example ETCAMAH 75 mg film-coated tablets (AstraZeneca AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Camizestrant shortage?
Not in the lists we track: Camizestrant has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Camizestrant works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Camizestrant works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Camizestrant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.